BAT5906 vs Brolucizumab-Dbll

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline

BAT5906

Developed by Bio-Thera Solutions

Phase 3 in Age-Related Macular Degenerationmonoclonal antibody
Partial signal

NCT05439629 · Phase 3 · completed

The study randomized 488 participants to BAT5906 or active treatment with Lucentis and masked participants, care providers, and investigators. Its primary outcomes were clinical measures of visual acuity, but the registry does not report whether the comparison was favorable or statistically significant, so the evidence remains limited pending results.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

No aligned efficacy figure on record for this race.

Brolucizumab-Dbll

Marketed by Novartis and partners

Approved in Age-Related Macular Degenerationantibody fragment (scFv)
Weak signal

NCT05672979 · Phase 3 · status unknown

This is a single-arm, unblinded study with no placebo or active comparator, so it cannot establish how much of any visual acuity change is attributable to brolucizumab itself. Results are not yet available.

No aligned efficacy figure on record for this race.

Results for Age-Related Macular Degeneration

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

BAT5906: no structured comparison results are available for Age-Related Macular Degeneration.

Brolucizumab-Dbll: registry results are on file for Age-Related Macular Degeneration, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT5906's landscape · Brolucizumab-Dbll's landscape